awmsg logo



zanamivir (Dectova®)


Reference No. 4130


Appraisal information

zanamivir (Dectova®) 10 mg/ml solution for infusion


Company: GlaxoSmithKline UK
BNF category: Infections
NMG meeting date: 04/09/2019
AWMSG meeting date: 16/10/2019
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

For the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when: The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Dectova should be used in accordance with official guidance
AWMSG Secretariat Appraisal Report (ASAR)
Download
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download